Compare Organon & Co. Common Stock (OGN) vs Sunrun Inc (RUN) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Sunrun (RUN) trades at $7.79, up 2.64% on the day, but remains in a bearish technical trend with strong selling pressure in moving averages. The stock shows attractive valuation metrics with P/E of 5.3 and P/B of 0.54, while consistently beating earnings expectations in recent quarters. Recent developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.

Despite positive analyst sentiment (62% buy ratings) and a $15.40 consensus price target representing 98% upside, RUN faces significant headwinds including negative operating cash flow, high debt levels (70.76% debt-to-asset ratio), and solar industry pressure from elevated borrowing costs. The stock trades near its analyst low target of $7.00, suggesting limited downside but requiring careful risk assessment.